Impact of 68Ga-DOTATATE PET/CT on the Management of Neuroendocrine Tumors: The Referring Physician's Perspective
NCT01873248
·
clinicaltrials.gov ↗
EARLY_PHASE1
Phase
COMPLETED
Status
100
Enrollment
OTHER
Sponsor class
Conditions
Neuroendocrine Tumors
Interventions
DRUG:
68Ga-DOTATATE
Sponsor
Jonsson Comprehensive Cancer Center